Continuing patient access to innovative treatment options
Continuing patient access to innovative treatment options
Send Your Letter
Submit your written public comments via your email
Feel free to customize the letter to your liking before sending
Open Pre-Filled Email Alternatively, you can manually send an email to policydraft@noridian.com
and moldx.policy@palmettogba.com with your message
Letter
Subject: Response to Proposed LCD for MolDX: Testing for Solid Organ Allograft Rejection
To Whom It May Concern,
My name is Dr. **[XX]**, I am a **[TITLE/SPECIALTY]** at
**[INSTITUTION]**. I have been caring for transplant patients for
over **[XX]** years, and have been using molecular diagnostics
for transplant recipients to diagnose rejection, avoid biopsies, and titrate
immunosuppression. My credentials include **[LIST ANY HONORS, MAJOR
ACADEMIC APPOINTMENTS, OR SOCIETY APPOINTMENTS]**.
The proposed LCD for MolDX: Molecular Testing for Solid Organ Allograft
Rejection, released on August 10, 2023, effectively limits my ability to
care for heart transplant recipients and imposes unrealistic testing
restrictions for my center and my patients. Specifically, if the current draft
LCD is finalized, we could see a rise in the number of unnecessary biopsies and
worse post-transplant outcomes
The policy’s changes to the frequency of molecular surveillance testing limited
by biopsy protocols, concurrent molecular testing and biopsy as well as
limitations on multi-modality testing in the same visit will impact our ability
to individualize immunosuppression and reduce toxicity and improve care of
patients who have received a heart transplant. The limitations will
stifle the innovation that is so desperately needed to improve patient care and
outcomes in heart transplant. My center currently uses **[GEP/DD-CFDNA
TEST]** on a **[FREQUENCY]** basis to assess for [disease
state]. With the changes imposed in the above, we will no longer be
able to provide the best transplant patient care.
I request MolDX to strongly reconsider implementing this proposed LCD which
would be vastly detrimental to my care of transplant recipients.
Sincerely,
**[SIGNATURE/NAME]**